Zim Laboratories Limited
Incorporated in 1989, Zim LaboratoriesLtd manufactures formulation drugs andpre formulation ingredients in India andmarkets and sells these within and outside India
What Zim files
- Others74
- Investor Meet33
- Important19
- Board Meeting13
- Updates9
- JV/Acquisition6
ZIM Laboratories has formed an Advisory Board for strategic guidance on business development. Comprising industry veterans like Mr. Annaswamy Vaidheesh, Mr. Gautam Saigal, and Mr. Girdhar Balwani, the board will advise on growth strategy, market expansion, and talent, supporting management's objectives.
ZIM Laboratories amended its Code of Fair Disclosure for Unpublished Price Sensitive Information. This operational update enhances transparency and strengthens internal controls for handling sensitive company data, impacting compliance with insider trading rules.
ZIM Labs received CDSCO approval for its innovative Naproxen + Esomeprazole FDC capsules, boosting its pain management & gastro-protective portfolio. A commercial supply agreement is signed, targeting India launch in FY26-27. This reinforces ZIM's strategy in differentiated generics.
ZIM Laboratories' Board has approved the closure of its step-down subsidiary, ZIM Laboratories Middle East DMCC. This operational change is pending UAE regulatory approvals. Notably, the subsidiary contributed Nil to the company's turnover, revenue, income, or net worth in the last financial year, indicating a minimal financial impact from its...
ZIM Laboratories' Australian subsidiary, ZIMTAS, has secured Marketing Authorization from the Therapeutic Goods Administration (TGA) for "Tamsulosin Hydrochloride and Dutasteride Capsules." This combination drug treats moderate to severe symptoms of benign prostatic hyperplasia (BPH), offering improved patient convenience through its fixed-dose format. This approval marks ZIM's second authorization in Australia,...